Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
pexelizumab in conjunction with CABG · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| pexelizumab in conjunction with CABG | DRUG | - |
Inclusion Criteria: * be at least 18 years of age; * have 2 or more of the following risk factors: • diabetes mellitus; • repeat CABG; • the need for urgent intervention, defined according to the ACC/AHA guidelines as being patients who are required to stay in the hospital due to medical factors...
Pexelizumab is an investigational small molecule being studied for use in coronary artery disease, specifically in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. It was evaluated in the Phase 3 PRIMO-CABG II trial to assess its effects in this surgical setting.
Pexelizumab is a small molecule designed to inhibit the complement system, a part of the immune response that can contribute to inflammation and tissue damage during cardiac surgery. By targeting this pathway, it aims to reduce complications associated with coronary artery bypass grafting.
Pexelizumab is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company sponsored the Phase 3 clinical trial evaluating the drug in patients with coronary artery disease.
Pexelizumab has completed Phase 3 clinical development for coronary artery disease. The Phase 3 trial, PRIMO-CABG II, has been completed, and the drug remains investigational as it is not approved for commercial use.
Pexelizumab was studied in the Phase 3 clinical trial NCT00088179, titled 'Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)'. This completed trial enrolled 4,000 participants across the United States, France, Germany, and the Netherlands.
Pexelizumab is not known by any alternative names. It is a distinct investigational compound developed by AstraZeneca for use in coronary artery disease, and no other drug names have been associated with it in clinical development.